Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

wala-heilmittel gmbh (3092764) - arteria basilaris bovis (pot.-angaben) - flüssige verdünnung zur injektion - teil 1 - flüssige verdünnung zur injektion; arteria basilaris bovis (pot.-angaben) (10794) 1 milliliter

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

wala-heilmittel gmbh (3092764) - arteria bovis (pot.-angaben) - flüssige verdünnung zur injektion - teil 1 - flüssige verdünnung zur injektion; arteria bovis (pot.-angaben) (15087) 1 milliliter

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

wala-heilmittel gmbh (3092764) - arteria basilaris bovis (pot.-angaben) - flüssige verdünnung zur injektion - arteria basilaris bovis (pot.-angaben) (10794) 1 milliliter

USA - engelsk - NLM (National Library of Medicine)

golden state medical supply, inc. - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. limitations of use: - use only if a clear diagnosis of migraine or cluster headache has been established. if a patient has no response to the first migraine or cluster headache attack treated with sumatriptan injection, reconsider the diagnosis before sumatriptan injection is administered to treat any subsequent attacks. - sumatriptan injection is not indicated for the prevention of migraine or cluster headache attacks. sumatriptan injection is contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions ( 5.1)] . - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway dis

Singapore - engelsk - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - fimasartan potassium trihydrate eqv fimasartan potassium; hydrochlorothiazide - tablet, film coated - fimasartan potassium trihydrate eqv fimasartan potassium 60.00 mg; hydrochlorothiazide 12.5 mg

Israel - engelsk - Ministry of Health

novartis israel ltd - nilotinib as monohydrate - capsules - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

Israel - engelsk - Ministry of Health

novartis israel ltd - nilotinib as hydrochloride monohydrate - capsules - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

USA - engelsk - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - almotriptan malate (unii: pjp312605e) (almotriptan - unii:1o4xl5sn61) - almotriptan 6.25 mg - adults axert® (almotriptan malate) is indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura. adolescents age 12 to 17 years axert® is indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). axert® should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with axert® , the diagnosis of migraine should be reconsidered before axert® is administered to treat any subsequent attacks. in adolescents age 12 to 17 years, efficacy of axert® on migraine-associated symptoms (nausea, photophobia, and phonophobia) was not established. axert® is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine [see contraindications (4.7)] . safety and effectiveness of axert® have not been established

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - sumatriptan, quantity: 100 mg/ml - spray, solution - excipient ingredients: sulfuric acid; monobasic potassium phosphate; purified water; dibasic sodium phosphate; sodium hydroxide - imigran s nasal spray is indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of imigran s in the treatment of basilar or hemiplegic migraine.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - sumatriptan, quantity: 200 mg/ml - spray, solution - excipient ingredients: dibasic sodium phosphate; purified water; monobasic potassium phosphate; sulfuric acid; sodium hydroxide - imigran nasal spray is indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of imigran in the treatment of basilar or hemiplegic migraine.